Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial

• Published in: BMC gastroenterology Vol. 16; no. 1; p. 79
• Main Authors: Lee, Ju Yup, Kim, Nayoung, Park, Kyung Sik, Kim, Hyun Jin, Park, Seon Mee, Baik, Gwang Ho, Shim, Ki-Nam, Oh, Jung Hwan, Choi, Suck Chei, Kim, Sung Eun, Kim, Won Hee, Park, Seon-Young, Kim, Gwang Ha, Lee, Bong Eun, Jo, Yunju, Hong, Su Jin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.07.2016; BioMed Central
• Subjects: Amoxicillin; Amoxicillin - adverse effects; Amoxicillin - therapeutic use; Antacids - adverse effects; Antacids - therapeutic use; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Bismuth; Bismuth - adverse effects; Bismuth - therapeutic use; Drug Administration Schedule; Drug Resistance, Bacterial; Drug therapy; Drug Therapy, Combination; Female; Gastritis - drug therapy; Gastritis - microbiology; Gastroenterology; Health aspects; Helicobacter infections; Helicobacter Infections - drug therapy; Helicobacter Infections - microbiology; Helicobacter pylori - drug effects; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Tetracycline - adverse effects; Tetracycline - therapeutic use; Treatment Failure; Quadruple; Bismuth; Helicobacter pylori; Eradication; Amoxicillin; Tetracycline

The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth qu...